/ /

  • linkedin
  • Increase Font
  • Sharebar

    New technologies on horizon to redefine drug delivery


    Ocular Therapeutix

    Best known for ocular sealant ReSure, Ocular Therapeutix is in late-stage development of drug-eluting intracanalicular inserts to deliver dexamethasone for post-surgical pain and inflammation, allergic conjunctivitis, and travoprost for glaucoma. Earlier stage inserts are being studied in dry eye and retinal vascular diseases. Retinal disease inserts are injected into the back of the eye.

    The company resubmitted its New Drug Application for Dextenza, its dexamethasone insert, after dealing with manufacturing issues. If approved as expected in 2017, Dextenza could be the first drug-eluting intracanalicular insert on the U.S. market. Glaucoma is next.

    The company is enrolling patients for phase III trials of QTX-TP, its travoprost-eluting insert, for glaucoma and ocular hypertension. The insert behaves much like Dextenza and is designed to last 90 days before replacement.

    Fred Gebhart
    The author is a correspondent for Urology Times, a sister publication.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results